Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension

Bryan Williams, Thomas M MacDonald, Mark Caulfield, J Kennedy Cruickshank, Gordon McInnes, Peter Sever, David J Webb, Jackie Salsbury, Steve Morant, Ian Ford, Morris J Brown, Bryan Williams, Thomas M MacDonald, Mark Caulfield, J Kennedy Cruickshank, Gordon McInnes, Peter Sever, David J Webb, Jackie Salsbury, Steve Morant, Ian Ford, Morris J Brown

Abstract

Introduction: Resistant hypertension is inadequately controlled blood pressure (BP) despite treatment with at least three BP-lowering drugs. A popular hypothesis is that resistant hypertension is due to excessive Na(+)-retention, and that 'further diuretic therapy' will be superior to alternative add-on drugs.

Methods and analysis: Placebo-controlled, random crossover study of fourth-line treatment when added to standard (A+C+D) triple drug therapy: ACE inhibitor or Angiotensin receptor blocker (A) +Calcium channel blocker (C)+Diuretic (D). Patients (aged 18-79 years) with clinical systolic BP ≥ 140 mm Hg (135 mm Hg in diabetics) and Home BP Monitoring (HBPM) systolic BP average ≥ 130 mm Hg on treatment for at least 3 months with maximum tolerated doses of A+C+D are randomised to four consecutive randomly allocated 12-week treatment cycles with an α-blocker, β-blocker, spironolactone and placebo. The hierarchical coprimary end point is the difference in HBPM average systolic BP between (in order) spironolactone and placebo, spironolactone and the average of the other two active drugs, spironolactone and each of the other two drugs. A key secondary outcome is to determine whether plasma renin predicts the BP response to the different drugs. A sample size of 346 (allowing 15% dropouts) will confer 90% power to detect a 3 mm Hg HBPM average systolic BP difference between any two drugs. The study can also detect a 6 mm Hg difference in HBPM average systolic BP between each patient's best and second-best drug predicted by tertile of plasma renin.

Ethics and dissemination: The study was initiated in May 2009 and results are expected in 2015. These will provide RCT evidence to support future guideline recommendations for optimal drug treatment of resistant hypertension.

Trial registration number: Clinicaltrials.gov NCT02369081, EUDract number: 2008-007149-30.

Keywords: Drug Treatment; Resistant Hypertension.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
PATHWAY 2 study design and flow chart.
Figure 2
Figure 2
Predicted probabilities model for plasma renin as the predictor of the best treatment option for resistant hypertension.

References

    1. Myat A, Redwood SR, Qureshi AC et al. . Resistant hypertension. BMJ 2012;345:e7473 10.1136/bmj.e7473
    1. Mancia G, Fagard R, Narkiewicz K et al. . 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159–219. 10.1093/eurheartj/eht151
    1. Calhoun DA, Jones D, Textor S et al. . Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403–19. 10.1161/HYPERTENSIONAHA.108.189141
    1. Krause T, Lovibond K, Caulfield M et al. . Management of hypertension: summary of NICE guidance. BMJ 2011;343:d4891 10.1136/bmj.d4891
    1. NICE hypertension guideline CG127. (accessed 26 May 2015).
    1. Düsing R. Optimizing blood pressure control through the use of fixed combinations. Vasc Health Risk Manag 2010;6:321–5. 10.2147/VHRM.S9989
    1. Pimenta E, Gaddam KK, Oparil S et al. . Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009;54:475–81. 10.1161/HYPERTENSIONAHA.109.131235
    1. Brown MJ. Renin: friend or Foe? Heart 2007;93:1026–33. 10.1136/hrt.2006.107706
    1. Chapman N, Dobson J, Wilson S et al. . Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839–45. 10.1161/01.HYP.0000259805.18468.8c
    1. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16(11 Pt 1):925–30. 10.1016/S0895-7061(03)01032-X
    1. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007;25:891–4. 10.1097/HJH.0b013e328014954d
    1. Hood SJ, Taylor KP, Ashby MJ et al. . The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007;116:268–75. 10.1161/CIRCULATIONAHA.107.690396
    1. British Hypertension Society how to measure blood pressure. (accessed 26 May 2015).
    1. Tomaszewski M, White C, Patel P et al. . High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014;100:855–61. 10.1136/heartjnl-2013-305063
    1. Pathway 1 BMJ Open 2015—to be inserted by BMJ Open ▪▪▪.
    1. Pathway 3 BMJ Open 2015—to be inserted by BMJ Open ▪▪▪.
    1. de la Sierra A, Segura J, Banegas JR et al. . Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011;57:898–902. 10.1161/HYPERTENSIONAHA.110.168948
    1. Myat A, Redwood SR, Qureshi AC et al. . Renal sympathetic denervation therapy for resistant hypertension: a contemporary synopsis and future implications. Circ Cardiovasc Interv 2013;6:184–97. 10.1161/CIRCINTERVENTIONS.112.000037
    1. Bhatt DL, Kandzari DE, O'Neill WW et al. . SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393–401. 10.1056/NEJMoa1402670
    1. James PA, Oparil S, Carter BL et al. . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507–20. 10.1001/jama.2013.284427
    1. Weber MA, Schiffrin EL, White WB et al. . Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014;32:3–15. 10.1097/HJH.0000000000000065
    1. Kjeldsen S, Feldman RD, Lisheng L et al. . Updated national and international hypertension guidelines: a review of current recommendations. Drugs 2014;74:2033–51. 10.1007/s40265-014-0306-5
    1. Chapman N, Chang CL, Dahlöf B et al. . ASCOT Investigators. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008;118:42–8. 10.1161/CIRCULATIONAHA.107.737957
    1. Laragh JH, Letcher RL, Pickering TG. Renin profiling for diagnosis and treatment of hypertension. JAMA 1979;241:151–6. 10.1001/jama.1979.03290280031022
    1. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002;39:982–8. 10.1161/01.HYP.0000016176.16042.2F

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅